Document:

EX-10.1

 Exhibit 10.1 

LETTER OF AGREEMENT 
 This Letter of
Agreement (“LOA”) is made and entered into as of this 11th day of July 2013 (“Effective Date”) between Argo Medical Technologies Ltd, an Israeli corporation having its principal place of business at Cohav
Yokneam Building, Yokneam Ilit P.O.B 161, Israel 20692 (“Customer”) and Sanmina Corporation and its subsidiaries, (collectively “Sanmina”), a Delaware corporation having its principal place of business at
2700 North First Street, San Jose, California 95134. 
 1. Customer and Sanmina are establishing a business relationship under which Customer may, among
other things, have Sanmina procure components, parts, and raw material (collectively “Components”) to manufacture, assemble, test, inspect configure and ship products detailed in documentation provided by Customer to Sanmina from
time to time (“Products”) in accordance with Customer’s purchase orders (“Orders”) submitted by Customer from time to time and accepted by Sanmina. The unit prices for the Products (“Prices”)
and the related financial liability for the procurement of Components for such Products (“Component Liability”) are as demonstrated in Appendix A hereto, as may be amended in writing by mutual consent of the parties
from time to time. This LOA is for the purpose of authorizing Sanmina to begin work immediately in lieu of a fully negotiated manufacturing services agreement (“MSA”). This LOA implies no commitment to enter into a MSA. Both parties
acknowledge that the execution of a MSA is contingent upon the mutual consent of the parties, and that should the MSA not be executed, the terms of this LOA shall be the sole governing agreement until terminated by either party. The parties agree
that all Orders accepted by Sanmina shall be based on the terms contained in this LOA, unless replaced by a MSA. Customer shall provide Sanmina’s Credit Department upon request a completed credit application. Sanmina shall provide Customer with
an initial credit limit, which shall be reviewed (and, if necessary, adjusted) from time to time with periodic financial updates from Customer in order to maintain a credit limit. The credit limit may be reduced upon five (5) days’ prior
written notice to Customer. In the event Customer exceeds its credit limit, Sanmina shall have the right to stop shipments of Product and stop loading new Orders and Forecasts until Customer makes a sufficient payment to bring its account within the
credit limit provided. 
 2. Prices are in U.S. Dollars and are subject to change by mutual consent. Prices were agreed by the parties based on (i) the
specifications, (ii) the projected volumes and run rates and other assumptions agreed by the parties and (iii) shipment FCA Sanmina’s facility of manufacture (Incoterms 2010). Prices specifically exclude (1) export licensing of
the Product and payment of broker’s fees, duties, tariffs or other similar charges, (2) taxes (other than those based on the net income of Sanmina); and (3) tooling or non-recurring expenses. Payment terms for Products are net thirty
(30) days after the date of the invoice which shall not be issued prior to shipment of such Product, provided that if Customer has no credit from Sanmina, such payment shall be made upon shipment (but subject always to
receipt of invoice). Customer shall pay Sanmina in advance for its Component Liability and Customer acknowledges that Sanmina will not place any orders for Components until such time as Sanmina has received the advance payment in full from Customer
to cover its Component Liability. It is clarified that Component Liability pre-paid by Customer for any Product shall be deducted from the Price payable for such Product. 

3. Customer may also provide Sanmina with forecasts for future requirements of Products (“Forecasts”). Provided that Sanmina has received an
advanced payment from Customer to cover its Component Liability in full, Sanmina will procure the quantity and type of Components necessary to manufacture the quantities of Product set forth in the Order and Forecast in accordance with its standard
material ordering policies available at www.sanmina-sci.com (“Policies”), and agrees to be financially responsible for all Components ordered in accordance with the Policies. Customer guarantees the obligations of each of its
subsidiaries or affiliates that places Orders or Forecasts pursuant to this LOA, and agrees to be jointly liable for all such obligations. 

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission. 

 4. Sanmina warrants that, for a period of one year from the date of manufacture of the Product, the Product will
be free from defects in workmanship. Products shall be considered free from defects in workmanship if they are manufactured in accordance with the most current version of IPC-A-600 or IPC-A-610. Sanmina shall, at its option and at its expense (and
as Customer’s sole and exclusive remedy for breach of any warranty), repair, replace or issue a credit for Product found to have defective workmanship during the warranty period. In addition, Sanmina will administer and pass through to Customer
(to the extent that they are transferable) manufacturers’ Component warranties and manage such warranties on Customer’s behalf, but does not independently warrant Components. THE SOLE REMEDY UNDER THIS WARRANTY SHALL BE THE REPAIR,
REPLACEMENT, OR CREDIT FOR DEFECTS AS STATED ABOVE. THIS WARRANTY IS THE SOLE WARRANTY GIVEN BY SANMINA AND IS IN LIEU OF ANY OTHER WARRANTIES EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, NON INFRINGEMENT,
AND FITNESS FOR A PARTICULAR PURPOSE, EACH OF WHICH IS SPECIFICALLY DISCLAIMED. Compliance with “RoHS”, “REACH” and other environmental legislation worldwide shall be as separately agreed by the parties. 

5. Customer may terminate this LOA or cancel an Order hereunder upon written notice to Sanmina. Sanmina will make commercially reasonable efforts to return
Components to vendors (provided that Sanmina shall not be so obligated for Components which have a line item value of less than $1000). Termination for Cause: either party may terminate this LOA or an Order for default if the
other party materially breaches and has not cured within thirty (30) days after the defaulting party is notified in writing of the material breach. Cure period for payment-related breaches shall be five (5) business days from receipt of
notice. Termination Based on other than Sanmina Breach: if this LOA or an Order is terminated by Customer for any reason other than a breach by Sanmina (including but not limited to a force majeure or termination for
convenience), Customer shall pay Sanmina: (1) the Order price for all finished Product existing at the time of termination; (2) Sanmina’s cost (including labor, Components, and mark-up on Components and labor as set forth in
Appendix A hereto) for work in process; and (3) Component inventory pursuant to Section 3 above. Termination Based on Sanmina’s Breach: if Customer terminates this LOA or cancels an Order as a result of an uncured
breach by Sanmina, Customer shall pay (1) the Order price for finished Product at the time of termination; (2) Sanmina’s cost (including labor, Components) for work in process; and (3) Component inventory pursuant to
Appendix A hereto and Section 3 excluding Sanmina markup or acquisition cost on Components relating to such uncured breach. Sanmina remains liable to Customer for damages pursuant to this LOA. Customer shall be
responsible for Sanmina’s documented cost to perform Customer-authorized non-recurring engineering or associated program duties. Provided that the Customer has no outstanding receivable, upon termination, Sanmina will deliver to Customer all
Products and Components. Further, upon termination Sanmina will promptly deliver to Customer any and all documentation and other property owned by Customer or for which Customer has paid under this LOA. 

6. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES, OR ANY DAMAGES WHATSOEVER
RESULTING FROM LOSS OF USE, DATA OR PROFITS, EVEN IF SUCH OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. FOR THE PURPOSE OF THIS SECTION, BOTH LOST PROFITS AND DAMAGES RESULTING FROM VALUE ADDED TO THE PRODUCT BY CUSTOMER SHALL BE
CONSIDERED CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL SANMINA’S LIABILITY FOR A PRODUCT (WHETHER ASSERTED AS A TORT OR CONTRACT CLAIM) EXCEED THE AMOUNTS PAID TO SANMINA FOR SUCH PRODUCT HEREUNDER. IN NO EVENT SHALL EITHER PARTY’S LIABILITY
FOR ALL CLAIMS ARISING OUT OF OR RELATING TO THIS LOA EXCEED THE LESSER OF EITHER $[***] OR [***] PERCENT ([***]%) OF THE TRAILING 

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission. 

 
12 MONTHS OF REVENUE FOR PRODUCT PAID FOR UNDER THIS LOA (THE “CAP”). THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE
CAP SHALL NOT APPLY TO LIMIT (i) CUSTOMER’S OBLIGATIONS HEREUNDER FOR TERMINATION/CANCELLATION PAYMENTS, AND (ii) THERE SHALL BE NO LIMITATIONS UNDER THIS SECTION ON A PARTY’S INDEMNIFICATION OBLIGATIONS. THE LIMITATIONS SET
FORTH IN THIS SECTION SHALL APPLY WHERE THE DAMAGES ARISE OUT OF OR RELATE TO THIS LOA. 
 7. Sanmina shall promptly indemnify, defend, and hold Customer
and its affiliates, shareholders, directors, officers, employees, contractors, agents, and other representatives harmless from all third party demands, claims, actions, causes of action, proceedings, suits, assessments, losses, damages, liabilities,
settlements, judgments, fines, penalties, interest, costs and expenses (including fees and disbursements of counsel) of every kind (collectively, “Claim(s)”) (a) based upon personal injury or death or injury to property
(other than damage to the Product itself, which is handled in accordance with Sanmina’s warranty) to the extent caused by the negligent or willful acts or omissions of Sanmina or its officers, employees, subcontractors or agents and/or
(b) arising from or relating to any actual or alleged infringement, misappropriation, or alleged violation of any intellectual property rights relating to Sanmina’s manufacturing processes. 

8. Customer shall promptly indemnify, defend, and hold Sanmina harmless from and against every Claim (a) based upon personal injury or death or injury to
property to the extent caused by the negligent or willful acts or omissions of Customer or its officers, employees, subcontractors, or agents, (b) arising from or relating to any actual or alleged infringement, misappropriation or alleged
violation of any intellectual property rights relating to a Product or portion of a Product, or (c) that the Product has a design defect or fails to comply with “RoHS”, “WEEE”, “REACH”’ (or other environmental
legislation) where such failure was not the responsibility of Sanmina. 
 9. The parties hereby agree to amend the Non-Disclosure Agreement
(“NDA”) entered into between the parties on April 25, 2013 such that the meaning of “Information” (as defined therein) shall also include (without derogation from any other meaning included therein) any
information related to Company’s shareholders (as the terms “Company” is defined therein). The NDA (as herein amended) is hereby incorporated herein by reference. A copy of the NDA (prior to the above amendment) is annexed
hereto as Appendix B. 
 10. Any and all intellectual property rights and other rights in and to the Products and its underlying technology,
including without limitation any derivatives thereof, and including further any changes or improvements therein made following contribution by Sanmina, shall be retained by Customer at all times, and no right therein is granted to Sanmina by virtue
of this LOA or otherwise. 
 11. This LOA and its attachments make up the entire agreement between the parties and supersede prior discussions, except for
the NDA incorporated in this LOA (as amended hereby). The parties expressly reject any pre-printed terms and conditions of any Order, acknowledgment, or any other form document of either party. The terms hereof may be amended only by a writing
executed by authorized representatives of the parties. This LOA will not be assigned by either party without the other party’s prior written consent except that subject to Section 3, Customer may assign its rights and obligations hereunder
without the need for consent to any affiliate or successor. Customer shall be the exporter of record for all Products shipped hereunder, and shall comply with all applicable export control statutes and regulations. This LOA shall be construed in
accordance with the substantive laws of California (excluding its conflicts of laws principles). The parties acknowledge and agree that the state courts of Santa Clara County or federal courts of the Northern District of California shall have
exclusive jurisdiction and venue to adjudicate any and all disputes in connection with this LOA. The provisions of the United Nations Conventions on Contracts for the International Sale of Goods shall not apply to this LOA. 

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission. 

 ACCEPTED AND AGREED TO: 
  

							
	SANMINA CORPORATION	 	CUSTOMER
				
	By:	 	 /s/ Mark Kraizer
	 	By:	 	 /s/ Ami Kraft

				
	Name:	 	 Mark Kraizer
	 	Name:	 	 Ami Kraft

				
	Title:	 	 VP & General Manager
	 	Title:	 	 CFO

				
		 	Sanmina Israel	 		 	 Argo

Medical Technologies Ltd.

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission. 

 LOA Appendix A 

Pricing 
 The price model agreed
between Sanmina and Argo Medical Technologies is as follows: 
 [***] 

The price model above and the Qty of the system refers to minimum order quantities (“MOQs”) to be agreed by the parties from time to time.

 Numerical Examples: 
 [***]

 NRE Charges: 
 [***] 

For extra engineering services Sanmina will charge [***] USD per hour. 

Component Liability: 
 Liability for Components shall be
determined between the Parties on a case-by-case basis. 

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission. 

 LOA Appendix B 

NDA 
  

 
 CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT 

WHEREAS, Argo Medical Technologies Ltd., having an address at Kochav Yokneam Building, POB 161, Yokneam 20692, Israel (hereinafter, together
with any affiliate thereof, “Company”), possesses confidential and proprietary information, methods and technology in connection with a device and methods for overcoming impeded locomotion disability, and related devices that
utilize similar principles and technology (hereinafter “Product”); 
 WHEREAS, Sanmina- having an address at P.O.B 102
Maa’lot 24952 Israel (hereinafter “Recipient”), desires to provide to the Company certain out sourcing services, as may be agreed in writing between the Company and Recipient form time to time (the “Services”);
and 
 WHEREAS, the Company may disclose to Recipient from time to time, at its discretion, certain Information (as defined below) to enable
Recipient to provide the Services (the “Purpose”) and,; 
 NOW, THEREFORE, to induce disclosure by the Company of such
Information, Recipient hereby undertakes and agrees as follows (the “Undertaking”): 
 1. The term “Information” means any
and all confidential and proprietary information of, or related to, the Company, including but not limited to any and all specifications, methods, prototypes, technology (including production technology), computer programs, and any and all records,
data, methods, techniques, processes, projections, plans, marketing and/or pricing information, materials, financial statements, memoranda, analyses, notes and any other data or information (in whatever form), as well as improvements and know-how
related thereto, relating to or concerning the Company, the Company’s suppliers or products, irrespective of form, but shall not include information that (i) was already known to or independently developed by the Recipient prior to its
disclosure as demonstrated by reasonable and tangible evidence satisfactory to the Company; (ii) shall have appeared in any printed publication or patent or shall have become a part of the public knowledge except as a result of breach of this
Undertaking by the Recipient; (iii) shall have been received by the Recipient from another person or entity having no obligation to the Company or the Company’s suppliers; or (iv) is approved in writing by the Company for release by
the Recipient. 
 2. Recipient (i) shall treat all Information as strictly confidential, (ii) shall not disclose any Information to any other
person or entity, other than Recipient’s employees, officers and directors, with a need to know who have confidentiality obligations at least as restrictive as those contained herein, without the prior written consent of the Company,
(iii) shall protect the Information with at least the same degree of care and confidentiality as it affords its own confidential information, at all times exercising at least a high degree of care in such protection, and (iv) shall not use
any Information in any manner except for Purpose. 

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission. 

 

 
  

 3. The Recipient acknowledges and agrees that the Information is and shall remain proprietary to the Company.
All copies of the Information shall be returned to the Company immediately upon request without retaining copies thereof. 
 4. It is understood and agreed
that any disclosure of Information shall not grant the Recipient any express, implied or other license or rights to patents or trade secrets of the Company, whether or not patentable, nor shall it constitute or be deemed to create a partnership,
joint venture or other like engagement. Further, Recipient agrees that it shall not remove or otherwise alter any of the trademarks or service marks, serial numbers, logos, copyrights, notices or other proprietary notices, if any, fixed or attached
to Information or any part thereof. 
 5. Neither this Undertaking nor the disclosure or receipt of Information shall constitute or imply any promise or
intention by Company to receive Services from the Recipient, or any commitment by Company with respect to present or future relationship with Recipient. 

6. The Recipient’s Undertakings herein shall be binding upon it and its affiliates, subsidiaries or successors and shall continue until permission is
specifically granted in writing to the Recipient by the Company to release the Information. 
 7. Recipient acknowledges that violation of its obligations
hereunder could cause the Company irreparable harm (including, but not limited to, the loss of patent rights) which could not be reasonably or adequately compensated for in damages resulting from an action of law and, therefore, that
Recipient’s agreements hereunder shall be enforceable both under law or in equity, by injunction or otherwise, without the necessity of posting a bond. 

8. This Undertaking shall be exclusively governed by, construed and enforced in accordance with the laws of the State of Israel, the courts of which shall
have exclusive jurisdiction over any dispute hereunder. A determination that any term of this Undertaking is void or unenforceable shall not affect the validity or enforceability of any other term or condition and any such invalid provision shall be
construed and enforced (to the extent possible) in accordance with the original intent of the parties as herein expressed. 
 IN WITNESS WHEREOF, the
Recipient has executed this Undertaking on April 25 , 2013. 
  

			
	RECIPIENT
		
	By:	 	 /s/ Nir Marko

		
	Title:	 	 Director Business Development

		
		 	Sanmina -Sci

  
 *** Confidential treatment has been
requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and
Exchange Commission.EX-10.2

 Exhibit 10.2 

STRATEGIC ALLIANCE AGREEMENT 
 This
Strategic Alliance Agreement is entered into as of September 24, 2013 (the “Effective Date”) by and between Yaskawa Electric Corporation, a limited company duly organized and existing under the law of Japan, having its address
at 2-1 Kurosakishiroishi, Yahatanishi-ku, Kitakyushu, Fukuoka, 806-0004, Japan. (Business Identity Code 2908-01-010767, hereinafter referred to as “YEC”) and Argo Medical Technologies Ltd., a private company duly organized and
existing under the law of Israel, having its address at Kokhav Yokneam Building, P.O. Box 161, Yokneam Ilit 20692, Israel (Business Identity Code 51-312137-6, hereinafter referred to as “ARGO”). 

RECITALS: 
  

	(A)	Argo is a venture company engaged in the business of healthcare robotics, and possesses valuable know-how regarding development, marketing and distribution of bipedal exoskeleton equipment for individuals with spinal
cord injuries, multiple sclerosis or cerebral palsy in North America and the European Union. 

  

	(B)	YEC is a leading company engaged in the business of electrical engineering and robotics, and possesses valuable know-how regarding development, manufacturing, marketing and distribution of various innovative solutions
globally. 

  

	(C)	The parties hereto recognize that the sales volume and demand of customers for healthcare equipment utilizing robotics technologies has increased and may increase further in the future. 

 

	(D)	The agreements have so far been reached between the parties hereto in regard to the formation and operation of a strategic alliance with the goal of evaluation, development and commercialization of such healthcare
products. 

 NOW, THEREFORE, YEC AND ARGO AGREE AS FOLLOWS: 

AGREEMENTS: 
  

	1.	SCOPE OF STRATEGIC ALLIANCE 

 The parties acknowledge that the purpose of this agreement
shall be to seek and develop possibilities for collaboration in the following areas: 
  

	 	(a)	Marketing, distribution, and commercialization of ARGO’s products by YEC, subject to the terms and conditions contained in this Agreement and a separate Distribution Agreement being entered into concurrently with
this Agreement (hereafter “DA”). 

  

	 	(b)	Marketing and distribution of future YEC products in the area of healthcare equipment by ARGO within the scope of its sales network. 

	 	(c)	Improvement of ARGO’s products by applying YEC’s know-how and expertise in the field of motion control and robotics, especially improvements necessary for YEC to successfully market ARGO’s products within
the scope agreed to in the DA. 

  

	 	(d)	Quality improvements of ARGO’s Products by applying YEC’s know-how and expertise in the field of motion control and robotics. 

 

	 	(e)	Definition of the responsibilities and areas of coverage of YEC and ARGO in the future research and development of ARGO’s products, as to be defined in detail on a case-by-case basis with separate joint development
agreements in the future. 

  

	2.	INVESTMENT BY YEC 

 As part of the implementation and execution of this Agreement, both
parties agree to enter into a separate Share Purchase Agreement (hereafter “SPA”), at the same time and subject to the execution of the DA. Upon the terms and subject to the conditions contained in the SPA, YEC has agreed to purchase
Series D-1 Convertible Preferred Shares of ARGO, par value NIS 0.01 each. The obligations of ARGO under this Agreement will not become invalid in case that YEC sells part or all of its shares of ARGO to another party. 

 

	3.	DISTRIBUTION OF ARGO’S PRODUCTS BY YEC 

 As part of the implementation and
performance of this Agreement, both parties are entering into the DA concurrently with this Agreement. Pursuant to the DA, and subject to its terms, ARGO agreed to appoint YEC as the exclusive distributor of its products in the Territory specified
therein, and YEC agreed to market and distribute Argo’s products in a professional manner. In case the DA is terminated in accordance with the terms and conditions of the DA, this provision shall be considered void. 

 

	4.	JOINT STEERING COMMITTEE 

 YEC and ARGO agree to pursue further opportunities for
collaboration in the areas of research and development, manufacturing, marketing and sales, for the purposes stated in this Agreement. As a platform to discuss such opportunities, YEC and ARGO agree to form a Joint Steering Committee (hereafter
“JSC”), which will meet at least four (4) times per year, once in every quarter, for the following purposes: 
  

	 	(a)	Subject to the DA being in effect, to review and share the progress of marketing and sales of ARGO Products by YEC and ARGO worldwide, as defined in the DA. 

 

	 	(b)	Subject to the DA being in effect, to establish sales targets and minimum purchase requirements for ARGO’s Products under the distribution relationship that is defined in the DA. 

	 	(c)	To discuss the possibilities of sales of YEC’s products in the healthcare field using ARGO’s sales network. 

  

	 	(d)	To discuss possibilities for improvements of ARGO’s Products, especially improvements necessary for YEC to successfully market ARGO’s products as defined in the DA, by granting YEC access to cost information
and applying YEC’s know-how and expertise in the field of motion control and robotics. 

  

	 	(e)	To discuss the responsibilities and areas of coverage of YEC and ARGO in the future research and development of ARGO Products, and to establish rules for proper compensation of the developing party for usage and/or
licensing of any invention, know-how and improvement created by such party in the course of joint development. 

  

	 	(f)	To discuss the potential for licensed manufacturing of ARGO’s Products by YEC. 

  

	 	(g)	To discuss the potential for quality improvements of ARGO’s Products by applying YEC’s know-how and expertise in the field of motion control and robotics. 

 

	5.	TERM 

 This Agreement will be effective as of the Effective Date. Unless sooner
terminated in accordance with the provisions hereof, the initial term of this Agreement (“Initial Term”) will be ten (10) years from the Effective Date, provided that at any time following the 7th
anniversary of such date, either party may terminate such strategic alliance upon not less than 60 days’ prior written notice to the other party. After the Initial Term, this Agreement may only be renewed if authorized officers of ARGO and YEC
agree in writing at least thirty (30) days before the expiration of the Initial Term or any renewal term to a renewal, including the period of the renewal term. “Term” means the Initial Term and any such renewal term. The
parties may terminate this Agreement during the Term as follows: 
  

	 	(a)	Termination by either party. Either party may terminate this Agreement by giving written notice of termination to the other party, which termination will be effective immediately upon such notice, if the other
party defaults in the performance of any of its material obligations provided for in this Agreement and fails to cure such default within sixty (60) days after receipt of notice from the other party of such default, unless a plan for remedying
such default has been proposed by the defaulting party and accepted by the non-defaulting party within such period. 

  

	 	(b)	Termination by both parties. ARGO and YEC may terminate this Agreement at any point provided that both parties agree in writing to such a termination. 

	6.	COORDINATION 

 A contact person for each party will coordinate the efforts of that party
under this agreement. The initial contact person for each party is as follows: 
  

					
	Yaskawa Electric Corporation	  	Argo Medical Technologies Ltd.	  	
			
	Kei Shimizu	  	Larry Jasinski	  	
	806-0004	  	33 Locke Drive, 2nd Floor	  	
	2-1 Kurosakishiroishi, Yahatanishi-ku	  	c/o Argo Medical Technologies, Inc	  	
	Kitakyushu, Fukuoka, 806-0004	  	Marlborough, MA 01752	  	
	Tel: +81 93 645 8949	  	USA	  	
	Fax: +81 93 645 8948	  	Tel: +1 (508)251-1154	  	
	E-mail: shimizu@yaskawa.co.jp	  	Fax: +1 (508)251-2970	  	
		  	E-mail: larry.jasinski@rewalk.com	  	

 A party’s contact person may be changed at any time by giving notice of the change to the other party. The
notice must include the name and contact information for the new contact person. The contact person for each party must be available at reasonable times and on reasonable notice to meet with, converse with, or otherwise communicate with the contact
person for the other party regarding issues arising under this agreement. 
  

	7.	RELATIONSHIP OF PARTIES 

 Nothing herein contained shall be construed to imply a joint
venture, partnership or principal-agent relationship between YEC and ARGO, and neither party shall have the right, power or authority to obligate or bind the other in any manner whatsoever, except as otherwise agreed in writing. During the
performance of any of the collaborative efforts set forth in this Agreement, ARGO’s employees will not be considered employees of YEC, and vice versa. 
  

	8.	INTELLECTUAL PROPERTY; CO-DEVELOPMENT, IMPROVEMENT, MODIFICATION 

 This agreement does
not give either party any rights, title or interest in the other party’s trade name, trademarks, copyrights, patents, trade secrets, know-how, proprietary data, confidential information, or other intellectual property (hereinafter collectively
“Intellectual Property”). Except as expressly stipulated in this Agreement, each party shall not without any prior written consent, use, copy, modify or license the other party’s Intellectual Properties supplied pursuant to
this Agreement. Unless otherwise agreed between the parties or stipulated in a separate related agreement such as the SPA or DA, each party confirms and agrees that any Intellectual Properties are hereby supplied to the other party on an “as
is” basis. There are no warranties by either party with respect to such Intellectual Properties, express or implied including the implied warranties of merchantability, fitness for a particular purpose and non-infringement. In the event that
the parties mutually agree to explore jointly in any manner, design and/or develop new products or improve or modify ARGO’s current products, the parties will negotiate, in good faith, in an attempt to conclude one or more appropriate license
agreements prior to either party’s use of the Intellectual Property of the other. 

	9.	CONFIDENTIAL INFORMATION 

 On or prior to the execution of this Agreement, both parties
shall sign a new Confidentiality and Non-Disclosure Agreement (hereinafter the “New NDA”) and both parties shall comply with any terms and conditions stipulated in the New NDA with respect to handling of any confidential information
disclosed by the other party hereunder. 
  

	10.	NON-SOLICITATION OF PERSONNEL 

 During the performance of the any of the collaborative
efforts set forth in this Agreement, each of ARGO and YEC agrees not to engage in any attempt whatsoever to hire, or to engage as independent contractors, the other’s employees or independent contractors during the term of the collaboration and
for a period of twelve (12) months following expiration or termination of the collaboration, except as may be mutually agreed in writing. 
  

	11.	REMEDIES 

 Each of the parties agrees that money damages will not be a sufficient remedy
for any breach of the above agreement relating to non-solicitation of personnel. Accordingly, a party will be entitled to specific performance and injunctive or other equitable relief as a remedy for any such breach, and the parties each further
agree to waive any requirement for the securing or posting of any bond in connection with such remedy. 
  

	12.	MISCELLANEOUS PROVISIONS 

  

	 	12.1.	Assignment 

 Neither this Agreement nor any part of this Agreement may be assigned or
transferred by either party without the prior written consent of the other party. Any assignment or transfer without such consent shall be null and void. 
  

	 	12.2.	Notice 

 All notices or other communications required or desired to be sent to either of the
parties will be invalid, unless made in writing and sent by registered or certified mail, postage prepaid, return receipt requested, or sent by recognized international courier service (e.g., Federal Express, DHL, etc.) with charges prepaid,
or by facsimile or electronic mail which is subject to confirmation by letter. The address for all notices or other communications required to be sent to ARGO or YEC will be the mailing address stated on the signature page to this Agreement, or such
other address as may be provided from one party to the other on at least ten (10) days prior written notice. Any such notice will be effective upon the date of receipt. 

	 	12.3.	Litigation Expense 

 If there is a default under this agreement, the defaulting party must
reimburse the non-defaulting party for all costs and expenses reasonably incurred by the non-defaulting party in connection with the default, including attorney’s fees. Additionally, if a suit or action is filed to enforce this agreement or
with respect to this Agreement, the prevailing party is entitled to reimbursement from the other party for all costs and expenses incurred in connection with the suit or action, including reasonable attorney’s fees at the trial level and on
appeal. 
  

	 	12.4.	Waiver 

 No waiver of any provision of this Agreement may be deemed, or will constitute, a
waiver or any other provision, whether or not similar, not will any waiver constitute a continuing waiver. No waiver will be binding unless executed in writing by the party making the waiver. 

 

	 	12.5.	Applicable Law 

 This agreement will be governed by and must be construed in accordance with
the laws of the State of Israel. All disputes arising pursuant to this Agreement shall be exclusively brought in the courts of competent jurisdiction residing in Tel Aviv, Israel. 

 

	 	12.6.	Entire Agreement 

 This Agreement constitutes the entire agreement between the parties with
regard to the matters contained herein, and may not be amended except in a writing signed by both parties. 
  

	 	12.7.	Severability 

 Immediately upon the execution by the parties of this Agreement, the
Confidentiality and Non-Disclosure Agreement of August 25TH, 2011 by and between the parties and the Letter as of July 5th, 2013
shall be terminated by mutual consent of the parties hereto, and become null and void. Notwithstanding the foregoing, should this Agreement be terminated or proven to be invalid, such termination or invalidation will in no way affect, impair or
invalidate any other related agreement including the SPA, DA and/or the New NDA, which will be in full force and effect. In addition, any amendment, invalidity or termination of the SPA, DA and/or the New NDA respectively or divestiture of Series
D-1 Convertible Preferred Shares of ARGO by YEC will not in any way affect, impair or invalidate this Agreement. 
  

	 	12.8.	Counterparts of the Agreement 

 This Agreement has been executed in two (2) identical
copies, one (1) for each party. 

					
	ARGO MEDICAL TECHNOLOGIES LTD.	 		 	YASKAWA ELECTRIC CORPORATION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]